- Home
- SGML vs EYPT Comparison
SGML vs EYPT Comparison
Compare SGML & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- EYPT
- Stock Information
- Founded
- SGML 2011
- EYPT 1987
- Country
- SGML Brazil
- EYPT United States
- Employees
- SGML N/A
- EYPT N/A
- Industry
- SGML Industrial Machinery/Components
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- SGML Industrials
- EYPT Industrials
- Exchange
- SGML Nasdaq
- EYPT Nasdaq
- Market Cap
- SGML 743.4M
- EYPT 741.0M
- IPO Year
- SGML N/A
- EYPT 2005
- Fundamental
- Price
- SGML $7.49
- EYPT $13.73
- Analyst Decision
- SGML Strong Buy
- EYPT Strong Buy
- Analyst Count
- SGML 1
- EYPT 6
- Target Price
- SGML $16.00
- EYPT $25.83
- AVG Volume (30 Days)
- SGML 2.6M
- EYPT 1.1M
- Earning Date
- SGML 11-14-2025
- EYPT 11-06-2025
- Dividend Yield
- SGML N/A
- EYPT N/A
- EPS Growth
- SGML N/A
- EYPT N/A
- EPS
- SGML N/A
- EYPT N/A
- Revenue
- SGML $134,494,014.00
- EYPT $51,898,000.00
- Revenue This Year
- SGML $40.75
- EYPT N/A
- Revenue Next Year
- SGML $39.56
- EYPT N/A
- P/E Ratio
- SGML N/A
- EYPT N/A
- Revenue Growth
- SGML N/A
- EYPT 2.99
- 52 Week Low
- SGML $4.25
- EYPT $3.91
- 52 Week High
- SGML $15.56
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- SGML 64.57
- EYPT 55.86
- Support Level
- SGML $6.33
- EYPT $12.54
- Resistance Level
- SGML $7.35
- EYPT $14.91
- Average True Range (ATR)
- SGML 0.48
- EYPT 0.83
- MACD
- SGML 0.11
- EYPT -0.11
- Stochastic Oscillator
- SGML 89.69
- EYPT 50.21
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.